1. inability to give informed consent, inability to understand the essence of the study 2. any vaccination/immunization carried out within 30 days prior to inclusion in study; 3. steroid therapy (excluding hormonal contraceptives) and/or immunoglobulins or other blood products, not completed 30 days before inclusion in the study; 4. covid-2019 disease or vaccination to prevent covid-2019 in less than six months before inclusion in the study 5. immunosuppressive drug therapy completed less than 3 months before inclusion in the study; 6. postponed less than one year prior to enrollment in the study acute coronary syndrome or stroke; 7. tuberculosis, chronic systemic infections; 8. exacerbation of rhinitis 9. burdened allergic history (presence in the anamnesis of information about anaphylactic shock, angioedema, polymorphic exudative eczema, serum sickness), hypersensitivity or allergic reactions to the introduction of immunobiological drugs, known allergic reactions to drug components, exacerbation allergic diseases on the day of inclusion in the study; 10. history of neoplasms (icd codes c00-d09); 11. donation of blood or plasma (in a volume of 450 ml or more) less than 2 months before inclusion in the study; 12. splenectomy in history; 13. neutropenia (decrease in the absolute number of neutrophils less than 1000/mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin less than 80 g/l), immunodeficiency in history within 6 months prior to enrollment in the study; 14. subjects with active human immunodeficiency virus disease syphilis, hepatitis b and c; 15. anorexia, protein deficiency of any origin; 16. history of alcoholism and drug addiction; 17. participation of the subject in any other interventional clinical trial during this study; 18. any other condition of the research subject that, in the opinion of the research physician, may prevent completion of the study in accordance with the protocol; 19. staff of research centers and other staff directly involved in conducting the study (principal investigator and members of the research team) and members of their families.

1. inability to give informed consent, inability to understand the essence of the study 2. any vaccination/immunization carried out within 30 days prior to inclusion in study; 3. steroid therapy (excluding hormonal contraceptives) and/or immunoglobulins or other blood products, not completed 30 days before inclusion in the study; 4. covid-2019 disease or vaccination to prevent covid-2019 in less than six months before inclusion in the study 5. immunosuppressive drug therapy completed less than 3 months before inclusion in the study; 6. postponed less than one year prior to enrollment in the study acute coronary syndrome or stroke; 7. tuberculosis, chronic systemic infections; 8. exacerbation of rhinitis 9. burdened allergic history (presence in the anamnesis of information about anaphylactic shock, angioedema, polymorphic exudative eczema, serum sickness), hypersensitivity or allergic reactions to the introduction of immunobiological drugs, known allergic reactions to drug components, exacerbation allergic diseases on the day of inclusion in the study; 10. history of neoplasms (icd codes c00-d09); 11. donation of blood or plasma (in a volume of 450 ml or more) less than 2 months before inclusion in the study; 12. splenectomy in history; 13. neutropenia (decrease in the absolute number of neutrophils less than 1000/mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin less than 80 g/l), immunodeficiency in history within 6 months prior to enrollment in the study; 14. subjects with active human immunodeficiency virus disease syphilis, hepatitis b and c; 15. anorexia, protein deficiency of any origin; 16. history of alcoholism and drug addiction; 17. participation of the subject in any other interventional clinical trial during this study; 18. any other condition of the research subject that, in the opinion of the research physician, may prevent completion of the study in accordance with the protocol; 19. staff of research centers and other staff directly involved in conducting the study (principal investigator and members of the research team) and members of their families.

inability to give informed consent, inability to understand the essence of the study any vaccination/immunization carried out within 30 days prior to inclusion in study; steroid therapy (excluding hormonal contraceptives) and/or immunoglobulins or other blood products, not completed 30 days before inclusion in the study; covid-2019 disease or vaccination to prevent covid-2019 in less than six months before inclusion in the study immunosuppressive drug therapy completed less than 3 months before inclusion in the study; postponed less than one year prior to enrollment in the study acute coronary syndrome or stroke; tuberculosis, chronic systemic infections; exacerbation of rhinitis burdened allergic history (presence in the anamnesis of information about anaphylactic shock, angioedema, polymorphic exudative eczema, serum sickness), hypersensitivity or allergic reactions to the introduction of immunobiological drugs, known allergic reactions to drug components, exacerbation allergic diseases on the day of inclusion in the study; history of neoplasms (icd codes c00-d09); donation of blood or plasma (in a volume of 450 ml or more) less than 2 months before inclusion in the study; splenectomy in history; neutropenia (decrease in the absolute number of neutrophils less than 1000/mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin less than 80 g/l), immunodeficiency in history within 6 months prior to enrollment in the study; subjects with active human immunodeficiency virus disease syphilis, hepatitis b and c; anorexia, protein deficiency of any origin; history of alcoholism and drug addiction; participation of the subject in any other interventional clinical trial during this study; any other condition of the research subject that, in the opinion of the research physician, may prevent completion of the study in accordance with the protocol; staff of research centers and other staff directly involved in conducting the study (principal investigator and members of the research team) and members of their families.

inability to give informed consent, inability to understand the essence of the study any vaccination/immunization carried out within 30 days prior to inclusion in study; steroid therapy (excluding hormonal contraceptives) and/or immunoglobulins or other blood products, not completed 30 days before inclusion in the study; covid-2019 disease or vaccination to prevent covid-2019 in less than six months before inclusion in the study immunosuppressive drug therapy completed less than 3 months before inclusion in the study; postponed less than one year prior to enrollment in the study acute coronary syndrome or stroke; tuberculosis, chronic systemic infections; exacerbation of rhinitis burdened allergic history (presence in the anamnesis of information about anaphylactic shock, angioedema, polymorphic exudative eczema, serum sickness), hypersensitivity or allergic reactions to the introduction of immunobiological drugs, known allergic reactions to drug components, exacerbation allergic diseases on the day of inclusion in the study; history of neoplasms (icd codes c00-d09); donation of blood or plasma (in a volume of 450 ml or more) less than 2 months before inclusion in the study; splenectomy in history; neutropenia (decrease in the absolute number of neutrophils less than 1000/mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin less than 80 g/l), immunodeficiency in history within 6 months prior to enrollment in the study; subjects with active human immunodeficiency virus disease syphilis, hepatitis b and c; anorexia, protein deficiency of any origin; history of alcoholism and drug addiction; participation of the subject in any other interventional clinical trial during this study; any other condition of the research subject that, in the opinion of the research physician, may prevent completion of the study in accordance with the protocol; staff of research centers and other staff directly involved in conducting the study (principal investigator and members of the research team) and members of their families.